News ASKA Pharmaceutical Holdings Co.,Ltd.

Equities

4886

JP3119660003

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-07-12 am EDT			5-day change	1st Jan Change
2,421 ^JPY	+0.88%		+0.08%	+35.71%

2023	Ha Tay Pharmaceutical JSC announced that it has received VND 180.6 billion in funding from ASKA Pharmaceutical Holdings Co.,Ltd.	CI
2023	ASKA Pharmaceutical Holdings Co.,Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

ASKA Pharmaceutical : May 31 2024 Licensing Agreement for Relugolix Combination Tablet for Endometriosis in the Gynecologic Disease Area	May. 31	PU
ASKA Pharmaceutical : April 25 2024 Personnel Changes of ASKA Pharmaceutical Holdings' Subsidiaries	Apr. 25	PU
ASKA Pharmaceutical : March 26 2024 ASKA Pharmaceutical Receives Approval for Partial Change of Manufacturing and Marketing Approval for RIFXIMA® TABLETS for Pediatric Indication	Mar. 26	PU
ASKA Pharmaceutical : March 21 2024 Newsweek International Features ASKA Pharmaceutical	Mar. 20	PU
Ha Tay Pharmaceutical JSC announced that it has received VND 180.6 billion in funding from ASKA Pharmaceutical Holdings Co.,Ltd.	Dec. 20	CI
ASKA Pharmaceutical : November 13 2023 ASKA Pharmaceutical Featured in a Special Feature in TIME Magazine	Nov. 14	PU
ASKA Pharmaceutical : September 21 2023 ASKA Pharmaceutical Holdings Participates at 2nd Femtech Tokyo	23-09-22	PU
ASKA Pharmaceutical : September 14 2023 Newsweek International Features ASKA Pharmaceutical	23-09-14	PU
ASKA Pharmaceutical : July 20 2023 ASKA Pharmaceutical Initiates Domestic Phase I II Clinical Trial of Relugolix Combination Tablet (AKP-022)	23-07-20	PU
ASKA Pharmaceutical : June 27 2023 Personnel Changes of Corporate Officers and Board Members of ASKA Pharmaceutical Holdings Subsidiaries	23-06-27	PU
ASKA Pharmaceutical : June 22 2023 ASKA Pharmaceutical Files an Application for Partial Change of Manufacturing and Marketing Approval for RIFXIMA	23-06-21	PU
ASKA Pharmaceutical : June 12 2023 Matters Subject to Measures for Electronic Provision of the Notice of the 2nd Annual General Meeting of Shareholders	23-06-11	PU
ASKA Pharmaceutical : June 12 2023 NOTICE OF CONVOCATION OF THE 2nd ANNUAL GENERAL MEETING OF SHAREHOLDERS	23-06-11	PU
ASKA Pharmaceutical : June 9 2023 ASKA Pharmaceutical Terminates Joint Research Agreement regarding the Drug Discovery Targeting Specific Ion Channels with RaQualia Pharma	23-06-09	PU
ASKA Pharmaceutical Holdings Co.,Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-11	CI
ASKA Pharmaceutical : April 24 2023 ASKA Pharmaceutical Enters into a Comprehensive Business Alliance Agreement on Femtech	23-04-24	PU
ASKA Pharmaceutical : April 21 2023 ASKA Pharmaceutical Holdings Installs CO₂-Free Electricity and Solar Power Generation Facilities	23-04-20	PU
ASKA Pharmaceutical : April 7 2023 ASKA licensee Hyundai files New Drug Application in Korea for OC Drospirenone	23-04-07	PU
ASKA Pharmaceutical : April 7 2023 ASKA Pharmaceutical Terminates Option Agreement with KinoPharma regarding Cervical Dysplasia Treatment	23-04-06	PU
ASKA Pharmaceutical : March 27 2023 Personnel Change of ASKA Pharmaceutical	23-03-27	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News ASKA Pharmaceutical Holdings Co.,Ltd.

Equities

4886

JP3119660003

Summary

Filters